Clinical Trials Logo

Kidney Cancer clinical trials

View clinical trials related to Kidney Cancer.

Filter by:

NCT ID: NCT00003308 Completed - Ovarian Cancer Clinical Trials

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

Start date: February 2, 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients with newly diagnosed brain metastases from kidney cancer, melanoma, or sarcoma.

NCT ID: NCT00003126 Completed - Kidney Cancer Clinical Trials

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer

Start date: June 1997
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy of post-operative high-dose bolus interleukin-2 (IL-2) in patients with high-risk renal cell carcinoma (RCC).

NCT ID: NCT00003107 Completed - Breast Cancer Clinical Trials

Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors

Start date: October 1997
Phase: Phase 1
Study type: Interventional

RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients who have hematologic cancer or solid tumor.

NCT ID: NCT00003103 Completed - Breast Cancer Clinical Trials

Chemotherapy in Treating Patients With Solid Tumors

Start date: August 1997
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors that have not responded to previous therapy.

NCT ID: NCT00003102 Completed - Kidney Cancer Clinical Trials

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

Start date: November 17, 1998
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients with advanced kidney cancer.

NCT ID: NCT00003091 Completed - Kidney Cancer Clinical Trials

High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma

Start date: January 1996
Phase: Phase 2
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer or melanoma cells. PURPOSE: Phase II trial to study the effectiveness of high-dose interferon alfa and interleukin-2 in treating patients with metastatic kidney cancer or melanoma.

NCT ID: NCT00002764 Completed - Ovarian Cancer Clinical Trials

Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma

Start date: April 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether surgery plus combination chemotherapy is more effective than surgery alone in treating patients with lung metastases from soft tissue sarcoma. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery plus combination chemotherapy with that of surgery alone in treating patients who have soft tissue sarcoma that has spread to the lung.

NCT ID: NCT00002737 Completed - Kidney Cancer Clinical Trials

Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer

Start date: March 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of the cancer cells and slow the growth of kidney cancer. Isotretinoin may help kidney cancer cells develop into normal cells. It is not yet known whether interferon alfa plus isotretinoin is more effective than interferon alfa alone for kidney cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without isotretinoin in treating patients who have metastatic kidney cancer.

NCT ID: NCT00002733 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Biological Therapy in Treating Patients With Metastatic Cancer

Start date: January 1996
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, in treating patients with metastatic cancer.

NCT ID: NCT00002641 Completed - Ovarian Cancer Clinical Trials

Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma

Start date: February 1995
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether giving chemotherapy after surgery is more effective than surgery alone in treating soft tissue sarcoma. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without chemotherapy in treating patients who have soft tissue sarcoma.